NCLEX Review Guide: Benign Prostatic Hyperplasia (BPH)

Definition and Etiology

• Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland that commonly affects men over 50 years of age. The exact cause is linked to age-related hormonal changes, specifically the increased production of dihydrotestosterone (DHT) within the prostate tissue.
• The prevalence increases with age, affecting approximately 50% of men by age 60 and up to 90% by age 85, making it one of the most common conditions in older male patients.

Anatomical Changes

• The prostate gland surrounds the proximal urethra just below the bladder neck. As the prostate enlarges, it compresses the urethra, creating mechanical obstruction to urine flow.
• The bladder responds to this obstruction by developing compensatory detrusor muscle hypertrophy, trabeculation, and formation of cellules or diverticula, which can lead to incomplete bladder emptying and urinary stasis.

Lower Urinary Tract Symptoms (LUTS)

• Symptoms of BPH are categorized as obstructive (related to voiding) and irritative (related to storage). Obstructive symptoms include weak urinary stream, hesitancy, intermittency, straining to void, and incomplete bladder emptying.
• Irritative symptoms include urinary frequency, urgency, nocturia, and urge incontinence. These symptoms result from detrusor muscle irritability secondary to outflow obstruction.

Complications

• Acute urinary retention (AUR) is a medical emergency characterized by sudden inability to urinate despite a full bladder, requiring immediate catheterization. This complication occurs in approximately 1-2% of men with BPH annually.
• Other serious complications include recurrent urinary tract infections, bladder stones, renal insufficiency, gross hematuria, and overflow incontinence due to chronic urinary retention.

Physical Examination

• The digital rectal examination (DRE) is a crucial component of the physical assessment, allowing evaluation of prostate size, consistency, symmetry, and tenderness. A normal prostate is approximately 20-30g, while BPH can cause enlargement to over 100g in severe cases.
• Physical assessment should also include abdominal examination to check for bladder distention, vital signs to rule out infection, and neurological assessment to exclude other causes of urinary symptoms.

Diagnostic Tests

• Prostate-specific antigen (PSA) testing is performed to help rule out prostate cancer, although PSA levels can be elevated in BPH as well. A PSA level above 4 ng/mL warrants further investigation for possible malignancy.
• Other diagnostic tests include urinalysis to rule out infection, uroflowmetry to measure urine flow rate, post-void residual volume assessment, and in some cases, cystoscopy or urodynamic studies to evaluate bladder function.

Alpha-1 Adrenergic Blockers

• Alpha-1 adrenergic blockers (medications that relax smooth muscle in the prostate and bladder neck) are first-line therapy for BPH. Common medications include tamsulosin (Flomax), alfuzosin (Uroxatral), doxazosin (Cardura), and terazosin (Hytrin).
• These medications work by relaxing smooth muscle in the prostate and bladder neck, reducing urethral resistance and improving urine flow. They provide relatively rapid symptom relief, usually within 2-4 weeks of initiating therapy.

5-Alpha Reductase Inhibitors

• 5-alpha reductase inhibitors (medications that block the conversion of testosterone to dihydrotestosterone) such as finasteride (Proscar) and dutasteride (Avodart) reduce prostate size by inhibiting the enzyme that converts testosterone to DHT.
• These medications can reduce prostate volume by 20-30% over 6-12 months, improving urinary flow and reducing the risk of complications such as acute urinary retention. They are most effective in men with significantly enlarged prostates (>40g).

Combination Therapy

• Combination therapy with an alpha blocker and a 5-alpha reductase inhibitor provides greater symptomatic relief than either medication alone for men with moderate to severe symptoms and enlarged prostates. This approach addresses both the dynamic (smooth muscle) and static (glandular tissue) components of obstruction.
• The Medical Therapy of Prostatic Symptoms (MTOPS) study demonstrated that combination therapy reduced the risk of BPH progression by 66% compared to placebo, significantly more than either drug class alone.

Indications for Surgery

• Surgical intervention is indicated when patients experience refractory symptoms despite medical therapy, recurrent urinary retention, recurrent UTIs, persistent gross hematuria, bladder stones, renal insufficiency, or when patients cannot tolerate medical therapy.
• Approximately 25-30% of men with BPH will eventually require surgical intervention, particularly those with severe symptoms or complications related to obstruction.

Surgical Procedures

• Transurethral resection of the prostate (TURP) remains the gold standard surgical treatment for BPH. This procedure involves removing the obstructing prostatic tissue using an endoscopic approach through the urethra, with no external incisions required.
• Newer, less invasive options include laser procedures (HoLEP, GreenLight PVP), transurethral incision of the prostate (TUIP), prostatic urethral lift (UroLift), and water vapor thermal therapy (Rezūm), each with specific advantages for selected patients.

Postoperative Care

• Following prostate surgery, patients typically have a three-way urinary catheter in place for continuous bladder irrigation to prevent clot formation and obstruction. The catheter is usually removed within 1-3 days when urine is clear or light pink.
• Common postoperative issues include hematuria, dysuria, urinary frequency, and urge incontinence, which generally improve over 4-6 weeks. Patients should avoid strenuous activity, straining, and sexual activity for 2-4 weeks to prevent bleeding.

Continuous Bladder Irrigation (CBI) Management

1. Assess the color of returning irrigation fluid hourly (should transition from bloody to pink to clear)
2. Maintain the prescribed flow rate to keep urine light pink or clearer
3. Ensure catheter patency by checking for clots or kinks in the tubing
4. Monitor for bladder spasms and administer antispasmodics as ordered
5. Assess for signs of TURP syndrome (hyponatremia, confusion, visual disturbances)
6. Document intake, output, and irrigation amounts separately

Assessment and Monitoring

• Comprehensive nursing assessment includes evaluation of urinary symptoms using validated tools such as the International Prostate Symptom Score (IPSS), which quantifies symptom severity on a scale of 0-35. Regular reassessment helps track disease progression and treatment efficacy.
• Nurses should assess for complications of BPH including urinary retention, UTIs, hematuria, and renal insufficiency. Monitoring post-void residual volumes provides objective data about bladder emptying efficiency.

Patient Education

• Patient education should include medication management, emphasizing the importance of adherence even when symptoms improve. For alpha blockers, patients should be warned about orthostatic hypotension and advised to take the first dose at bedtime.
• Lifestyle modifications include avoiding bladder irritants (caffeine, alcohol), managing fluid intake (especially before bedtime), double voiding techniques, and pelvic floor exercises to improve bladder control.

Catheter Management

• For patients with acute urinary retention, catheterization provides immediate relief. Nurses must understand proper catheter insertion techniques for males with enlarged prostates, including using a coudé (curved-tip) catheter when standard catheters are difficult to pass.
• Patients requiring long-term catheterization due to chronic retention should receive education about catheter care, signs of complications (infection, blockage, dislodgement), and the importance of adequate hydration to prevent catheter encrustation.

Male Catheterization with Enlarged Prostate

1. Gather appropriate supplies including a 16-18Fr coudé catheter if available
2. Position patient supine with legs slightly spread
3. Perform thorough cleansing of the penis using aseptic technique
4. Apply sterile lubricant generously to the catheter
5. Hold penis perpendicular to body and apply gentle traction
6. Insert catheter gently, pausing if resistance is met
7. If using a coudé catheter, keep the curved tip facing upward (12 o'clock position)
8. Advance catheter to the bifurcation and inflate the balloon only when urine flow is confirmed
9. Document the procedure, amount of urine obtained, and patient's response

• BPH is a progressive, non-malignant enlargement of the prostate gland affecting most men as they age, causing both obstructive and irritative lower urinary tract symptoms.
• First-line pharmacological management includes alpha-1 blockers for rapid symptom relief and 5-alpha reductase inhibitors for prostate size reduction, with combination therapy offering superior outcomes for moderate to severe cases.
• Surgical intervention is indicated for refractory symptoms or complications, with TURP remaining the gold standard despite newer, less invasive alternatives.
• Nursing management focuses on symptom assessment, medication management, complication prevention, and comprehensive patient education about lifestyle modifications and self-care strategies.

BPH vs. Prostate Cancer

Alpha Blockers vs. 5-Alpha Reductase Inhibitors

Acute vs. Chronic Urinary Retention

Memory Aids